Mark Warren, MD: Formulary access is very important when we choose an insulin product or any product for that matter. So, when I choose a product, I want to have the best product. I choose it, I teach the patient about it, they go to get it filled. Yet, it’s not on their formulary, and then that work falls back on my staff to get the preapproval process going or, if it’s rejected, to choose another product. That requires more training of the patient, perhaps a different device, and explaining to them differences in the insulin and why we have to change. So, formulary access is a big issue for our office because it does take a lot of my staff time and a preauthorization process. That does play a role when we’re deciding on insulin. If one is equally as good and a formulary has it, then I’ll choose the one that the formulary has—if I know the formulary. But generally, I don’t really know the formulary. Our EMR doesn’t necessarily tell me the formulary, or its own formulary, and if it does, it’s usually wrong. So, I will generally prescribe the insulin that I think is the best for them. But formulary access is a big problem for us, and that does present a barrier in our ability to take care of our patients and a lot of frustration from our staff and our patients’ standpoint that they can’t get the insulin the doctor prescribed, the insulin that the physician thought was best for them. So, it’s a big barrier and a big problem for us.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays
April 17th 2025Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.
Read More
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More